Please use this identifier to cite or link to this item:
|Scopus||Web of Science®||Altmetric|
|Title:||BCR-ABL1 doubling times more reliably assess the dynamics of CML relapse compared with the BCR-ABL1 fold rise: implications for monitoring and management|
|Citation:||Blood, 2012; 119(18):4264-4271|
|Publisher:||Amer Soc Hematology|
|Susan Branford, David T. Yeung, Jodi A. Prime, Soo-Young Choi, Ju-hee Bang, Jin Eok Park, Dong-Wook Kim, David M. Ross and Timothy P. Hughes|
|Abstract:||Rising BCR-ABL1 transcripts indicate potential loss of imatinib response in CML. We determined whether the BCRABL1 doubling time could distinguish nonadherence from resistance as the cause of lost response. Distinct groups were examined: (1) acquired clinical resistance because of blast crisis and/or BCRABL1 mutations; and (2) documented imatinib discontinuation/interruption. Short doubling times occurred with blast crisis(median, 9.0 days; range, 6.1-17.6 days; n = 12 patients), relapse after imatinib discontinuation in complete molecular response (median, 9.0 days; range, 6.9-26.5 days; n = 17), and imatinib interruption during an entire measurement interval(median, 9.4 days; range, 4.2-17.6 days; n = 12; P = .72). Whereas these doubling times were consistently short and indicated rapid leukemic expansion, fold rises were highly variable: 71-, 9.5-, and 10.5- fold, respectively. The fold rise depended on the measurement interval, whereas the doubling time was independent of the interval. Longer doubling times occurred for patients with mutations who maintained chronic phase (CP: median, 48 days; range, 17.3-143 days; n = 29; P <.0001). Predicted short and long doubling times were validated on an independent cohort monitored elsewhere. The doubling time revealed major differences in kinetics according to clinical context. Long doubling times observed with mutations in CP allow time for intervention. A short doubling time for a patient in CP should raise the suspicion of nonadherence.|
|Keywords:||Humans; Blast Crisis; Leukemia, Myeloid, Chronic-Phase; Disease Progression; Recurrence; Benzamides; Piperazines; Pyrimidines; Fusion Proteins, bcr-abl; RNA, Messenger; RNA, Neoplasm; Antineoplastic Agents; Protein Kinase Inhibitors; Drug Monitoring; Drug Administration Schedule; Retrospective Studies; Drug Resistance, Neoplasm; Time Factors; Disease Management; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Randomized Controlled Trials as Topic; Medication Adherence; Biomarkers, Tumor; Imatinib Mesylate|
|Rights:||Copyright © 2012 by American Society of Hematology|
|Appears in Collections:||Medicine publications|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.